
LSTA Stock Forecast & Price Target
LSTA Analyst Ratings
Bulls say
Lisata Therapeutics Inc. shows a strong positive outlook driven by the promising preliminary data from the Cohort A study, which indicated an encouraging trend in overall survival and included four complete responses among patients treated with certepetide. The advancements in the development of certepetide as the company's lead candidate are noteworthy, with data from Cohort B suggesting that a second dose may enhance progression-free survival (PFS) and overall response rate (ORR) for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). These results highlight the therapeutic potential of certepetide in effectively targeting and treating solid tumors, positioning Lisata Therapeutics favorably within the clinical-stage pharmaceutical market.
Bears say
The financial outlook for Lisata Therapeutics Inc is predominantly negative due to the potential for failed or inconclusive results from ongoing clinical trials, which could significantly hinder the company's advancement in the development of its investigational product, certepetide. Additionally, there is a notable concern regarding the company's ability to secure adequate funding necessary to continue its research and development efforts, which poses a further risk to its operational viability. These fundamental challenges highlight the uncertainties surrounding the company's prospects, particularly in a highly competitive therapeutic landscape for the treatment of solid tumors.
This aggregate rating is based on analysts' research of Lisata Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LSTA Analyst Forecast & Price Prediction
Start investing in LSTA
Order type
Buy in
Order amount
Est. shares
0 shares